A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma.

Trial Profile

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Alisertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Millennium media release.
    • 06 Dec 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top